What is HC Wainwright’s Forecast for UBX FY2025 Earnings?

Unity Biotechnology, Inc. (NASDAQ:UBX) – Equities research analysts at HC Wainwright upped their FY2025 EPS estimates for Unity Biotechnology in a research note issued on Monday, March 10th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.45) per share for the year, up from their prior forecast of ($1.71). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2026 earnings at ($0.42) EPS, FY2027 earnings at $0.23 EPS and FY2028 earnings at $0.68 EPS.

Separately, Chardan Capital reaffirmed a “buy” rating and issued a $6.00 target price on shares of Unity Biotechnology in a research report on Monday.

Unity Biotechnology Price Performance

NASDAQ UBX opened at $1.79 on Wednesday. The firm’s 50-day moving average is $1.88 and its two-hundred day moving average is $1.51. Unity Biotechnology has a 12 month low of $0.94 and a 12 month high of $3.10. The stock has a market capitalization of $30.16 million, a P/E ratio of -1.37 and a beta of 1.02.

Institutional Trading of Unity Biotechnology

A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC lifted its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 9.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 163,242 shares of the company’s stock after purchasing an additional 14,199 shares during the quarter. Geode Capital Management LLC owned about 0.97% of Unity Biotechnology worth $240,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 29.49% of the company’s stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.